Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Athira Pharma Inc
(NQ:
ATHA
)
2.615
-0.025 (-0.95%)
Streaming Delayed Price
Updated: 1:15 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Athira Pharma Inc
< Previous
1
2
3
4
5
6
7
Next >
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023
Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
March 23, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
March 08, 2023
Company to highlight potential of its small molecule therapeutics that enhance the HGF/MET system to treat a variety of neurodegenerative diseases
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma, Inc. (NASDAQ:ATHA) Investor Alert: Investigation over Potential Wrongdoing
March 06, 2023
San Diego, CA -- (SBWIRE) -- 03/06/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Athira Pharma, Inc.
Via
SBWire
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Via
MarketBeat
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
February 01, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc.
January 18, 2023
San Diego, CA -- (SBWIRE) -- 01/18/2023 -- The Shareholders Foundation announced an update in the lawsuit that was filed on behalf of certain investors in Athira Pharma, Inc. (NASDAQ:ATHA).
Via
SBWire
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
December 21, 2022
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
December 05, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
December 01, 2022
Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
November 29, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
November 28, 2022
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 21, 2022
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
November 16, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
November 10, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present at Stifel 2022 Healthcare Conference
November 09, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
November 07, 2022
Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
October 17, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
May 27, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 20, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
May 05, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA
April 29, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 15, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
NASDAQ:ATHA Long Term Investor Notice: Investigation of Potential Wrongdoing at Athira Pharma, Inc.
October 01, 2021
San Diego, CA -- (SBWIRE) -- 10/01/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Athira Pharma, Inc.
Via
SBWire
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
ATHIRA SHAREHOLDER NOTICE
August 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Initial Public Offering
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
ATHIRA SHAREHOLDER ALERT
August 27, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Initial Public Offering
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.